KTRA Stock Technical Analysis | Kintara

Technical Analysis for KTRA - Kintara Therapeutics, Inc.

Grade	Last Price	% Change	Price Change
D	0.15	10.68%	0.01

KTRA closed up 10.68 percent on Thursday, May 16, 2024, on 1.24 times normal volume.

3 Watchers

Trend Table & Recent EOD Trading Signals

ADX	Long Term	Intermediate Term	Short Term
Strong	Down	Up	Flat

Date	Alert Name	Type	% Chg
May 16	Crossed Above 20 DMA	Bullish	0.00%
May 16	Pocket Pivot	Bullish Swing Setup	0.00%
May 16	Wide Bands	Range Expansion	0.00%
May 16	Oversold Stochastic	Weakness	0.00%
May 15	Stochastic Reached Oversold	Weakness	10.68%
May 15	Wide Bands	Range Expansion	10.68%
May 15	Gapped Up	Strength	10.68%
May 15	Oversold Stochastic	Weakness	10.68%
May 14	1,2,3 Pullback Bullish	Bullish Swing Setup	13.36%
May 14	Non-ADX 1,2,3,4 Bullish	Bullish Swing Setup	13.36%

Recent Intraday Alerts

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Basic chart:

Profile

Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs.

Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Pharmaceutical Cancer Therapies Novel Cancer Enzon Pharmaceuticals

Is KTRA a Buy, Sell or Hold?

Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date	Title
May 15	Kintara Therapeutics GAAP EPS of -$0.05
May 14	Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
Apr 26	Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Apr 4	Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Apr 3	Kintara to merge with TuHURA Bio in all-stock deal
Apr 3	Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Mar 28	Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Mar 27	Kintara Therapeutics expands REM-001 study to include patients on pembrolizumab
Mar 27	Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
Feb 14	Kintara Therapeutics GAAP EPS of -$0.24

Comments

Indicators

Pivot Point Level	Traditional / Classic	Fibonacci	Demark	Woodie	Camarilla
Resistance 4 (R4)					0.19
Resistance 3 (R3)	0.18	0.17			0.18
Resistance 2 (R2)	0.17	0.16		0.17	0.18
Resistance 1 (R1)	0.16	0.15	0.16	0.16	0.17
Pivot Point	0.14	0.14	0.15	0.14	0.14
Support 1 (S1)	0.13	0.13	0.14	0.13	0.12
Support 2 (S2)	0.12	0.13		0.12	0.11
Support 3 (S3)	0.10	0.12			0.11
Support 4 (S4)					0.10